News Ticker

[ December 9, 2023 ] Product Release Coordinator- QA Pharmaceutical / Biotech – Full Time Days – Grifols – Los Angeles, CA Los Angeles Biotech Jobs
[ December 8, 2023 ] “Frozen” Composer Christophe Beck and Kristen Bell Reunite at Education Through Music-Los Angeles Gala Los Angeles Biotech News
[ December 8, 2023 ] Medical Lab Scientist – Techsara solutions Inc – Mission Viejo, CA Los Angeles Biotech Jobs
[ December 8, 2023 ] City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research Los Angeles Biotech News
[ December 8, 2023 ] UCLA researchers lay groundwork to study effects of maternal diabetes on fetal metabolism and development Featured News

Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

February 8, 2021 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off

SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are anticipated June 2021.

Copyright © 2023 Biotech Networks, LLC